Calcent 100
Rx- Generic:
- Acalabrutinib
- Company:
- Incepta Pharmaceuticals Ltd.
- Dosage form:
- Tablet
- Pack size:
- Box (12 Tablet)
৳ 1,200/unit
Pack: ৳ 14,400
Price comparison
- This brand
- ৳ 1200
This is the cheapest brand of this generic
Compared against 1 brands
At a glance
Generic Name: Acalabrutinib Dosage Form: Oral Capsule Therapeutic Class: Tyrosine Kinase Inhibitor Pharmacological Class: Bruton's Tyrosine Kinase (BTK) Inhibitor Indications: Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Prescription Status: Prescription Only Medicine.
Indications
Mantle Cell Lymphoma (after at least one prior therapy) Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)
Dosage
Recommended dose: 100 mg twice daily (every 12 hours). Continue until disease progression or unacceptable toxicity.
Side effects
Anaemia Neutropenia Thrombocytopenia Upper respiratory tract infection Headache Diarrhoea Musculoskeletal pain
Precautions & warnings
Serious hemorrhagic events, including fatal events, reported; the mechanism for the bleeding events is not well understood; acalabrutinib may further increase hemorrhage risk in patients receiving antiplatelet or anticoagulant therapies, and patients should be monitored for signs of bleeding; consider the benefit-risk of withholding acalabrutinib for 3-7 days presurgery and postsurgery depending on the type of surgery and the risk of bleeding Serious infections (bacterial, viral, or fungal), including fatal events and opportunistic infections, reported; monitor for infection and consider prophylaxis in patients who are at increased risk for opportunistic infections Cytopenias reported, including neutropenia, anemia, and thrombocytopenia; assess complete blood cell counts monthly during treatment Second primary malignancies, including nonskin carcinomas, have occurred in patients with hematologic malignancies treated with acalabrutinib; the most frequent was skin cancer; advise patients regarding need for protection from sun exposure Atrial fibrillation and flutter occurred (rare) during clinical trials; monitor patients and manage as appropriate